ALSO NOTED: Alfacell shares surge; Galapagos signs collaboration pacts; and much more...

> Alfacell's shares surged 13 percent after researchers reported that onconose demonstrated promising results in a preclinical study. Report

> The service division of Belgium's Galapagos has signed two new collaboration pacts with Ono Pharmaceutical. The pacts call for BioFocus DPI to provide screening services and medical chemistry projects. Report

> Kosan Biosciences announced that its cancer drug tanespimycin passed a significant safety test. Report

> TomoTherapy has set the terms for its IPO, pricing 10.9 million shares at a range of $15 to $17. Report

> The FDA has approved GlaxoSmithKline's antibacterial Altabax for impetigo. Release

> Sirion Therapeutics has received the FDA's orphan drug designation for its anti-viral therapy, ganciclovir, for the treatment of acute herpetic keratitis. Release

> The FDA will give a priority review for GPC Biotech's chemotherapy satraplatin in combination with the steroid prednisone for hormone-refractory prostate cancer patients who have failed prior chemotherapies. Report

> Cytochroma and Genzyme have settled a lawsuit regarding alleged misappropriation of trade secrets. Release

And Finally… Cambodia has confirmed a new outbreak of bird flu just days after a 13-year-old girl died from the virus. Report

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.